|1.||Aubry, Dominique: 4 articles (09/2015 - 04/2009)|
|2.||Duchosal, Michel A: 4 articles (09/2015 - 04/2009)|
|3.||Bruzzone, Santina: 4 articles (09/2015 - 06/2009)|
|4.||Nahimana, Aimable: 4 articles (09/2015 - 04/2009)|
|5.||Nencioni, Alessio: 4 articles (09/2015 - 06/2009)|
|6.||Sehested, Maxwell: 4 articles (01/2013 - 01/2010)|
|7.||Ballestrero, Alberto: 3 articles (09/2015 - 06/2009)|
|8.||Patrone, Franco: 3 articles (09/2015 - 06/2009)|
|9.||Cea, Michele: 3 articles (09/2015 - 06/2009)|
|10.||Thougaard, Annemette V: 3 articles (06/2010 - 04/2009)|
|1.||B-Cell Lymphoma (Lymphoma, B Cell)
01/01/2013 - "APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. "
11/01/2003 - "For efficacy studies, FK-866 was administered orally twice daily at doses of 6 and 10 mg/kg or twice daily at doses of 3 and 5 mg/kg on days 14 to 19 after tumor cell inoculation. "
04/01/2014 - "Recently, it has been shown that APO866 induces apoptosis and autophagy in human hematological cancer cells, but the role of autophagy in APO866-induced cell death remains unclear. "
02/01/2014 - "Compared with untreated tumors, APO866 and radiation alone resulted in tumor growth delays of 14 days and 33 days, respectively, whereas the combination showed a significantly increased tumor growth delay of 65 days. "
01/01/2013 - "Tumors treated with APO866 had volumes that were 114% (24 h), 128% (48 h) and 130% (Day 7) relative to baseline volumes at Day 0. "
|3.||Hematologic Neoplasms (Hematological Malignancy)
06/04/2009 - "APO866 activity in hematologic malignancies: a preclinical in vitro study."
04/01/2014 - "Altogether, our results indicated that autophagy is essential for APO866 cytotoxic activity on cells from hematological malignancies and also indicate an autophagy-dependent CAT degradation, a novel mechanism for APO866-mediated cell killing. "
04/02/2009 - "The results support the potential of APO866 for treating hematologic malignancies."
11/01/2010 - "Activation of the extrinsic apoptotic cascade with TRAIL selectively amplifies the sequelae of Nampt inhibition in leukemia cells, and appears as a promising strategy to enhance APO866 activity in hematological malignancies."
04/02/2009 - "The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies."
04/01/2011 - "The NAMPT inhibitor, APO866, is currently in clinical phase II trials in lymphomas. "
09/01/2014 - "In vivo, combined administration of APO866 with RTX in a laboratory model of human aggressive lymphoma significantly decreased tumor burden and prolonged survival over single-agent treatment. "
09/01/2014 - "APO866 is an inhibitor of nicotinamide adenine dinucleotide (NAD) biosynthesis that exhibits potent anti-lymphoma activity. "
09/01/2014 - "The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody."
04/01/2014 - "A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis."
|5.||Glioblastoma (Glioblastoma Multiforme)
10/01/2015 - "Our previous study showed that APO866 inhibits the proliferation of C6 glioblastoma cells, but failed to induce apoptosis. "
10/01/2015 - "Using LC3 immunofluorescence imaging and transmission electron microscopy detection, we found that APO866 at 1-100 nM induced autophagy in C6 glioblastoma cells. "
10/01/2015 - "Since APO866 inhibits cellular metabolism and such metabolic stress is closely related with autophagy, thus we determined whether APO866 can induce autophagy in C6 glioblastoma cells and whether the autophagy induced by APO866 is pro-death or pro-survival. "
01/15/2012 - "Taken together, our results indicated that APO866 is a potent growth inhibitor against glioblastoma through targeting NAMPT."
01/15/2012 - "We found that APO866 inhibited the growth of C6 glioblastoma cells with IC(50) in nano-molar range. "
|2.||N- (6- chlorophenoxyhexyl)- N''- cyano- N''- 4- pyridylguanidine (CHS 828)
|3.||1- (2- (2- (2- (2- methoxyethoxy)ethoxy)ethoxy)ethoxycarbonyloxymethyl)- 4- (N'- cyano- N''- (6- (4- chlorophenoxy)hexyl)- N- guanidino)pyridinium
|5.||Caspase 3 (Caspase-3)
|6.||Reactive Oxygen Species (Oxygen Radicals)
|1.||Heterologous Transplantation (Xenotransplantation)